Redefining Respiratory Care

AATec develops a new class of biotherapeutics for the treatment of inflammatory respiratory diseases. Our mission is to provide broadly active causative treatments that go beyond symptom management. 

Chronic respiratory diseases are on the rise worldwide, driven by lifestyle, demographics, environmental pollution and increasing infections. Hundreds of millions of people suffer from diseases like COPD, asthma, bronchiectasis and pulmonary infections creating substantial challenges for humans, healthcare systems, and economies globally. In addition, rare diseases such as ARDS or bronchiolitis obliterans syndrome (BOS) cause extensive burden in healthcare. Treatment options are still limited despite the significant medical need.

AATec is committed to closing this gap by targeting the root causes of neutrophilic inflammation. We have developed a drug platform based on a novel proprietary version of recombinant version of alpha-1 antitrypsin (AAT) that has broad multimodal therapeutic effects against key disease drivers. Using our dedicated protein nebulization technology we apply our drugs directly to the lungs for optimal effect and safety. 

Our novel recombinant drug platform can overcome the current obstacles in neutrophilic lung diseases, restoring respiratory function and improving the quality of life of millions worldwide.